Supported by unrestricted educational grants from Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision
Upon completion of this activity, the participant should be able to:
Describe and identify current and emerging presbyopia and astigmatism correcting IOLs
Describe elements of a standardized postoperative outcomes assessment for patients with presbyopia and/or astigmatism correcting IOLs
Cite literature on the impact of rotational error on the quality of vision and patient satisfaction in toric IOL patients
Marc R. Bloomensetin, OD, FAAO
Schwartz Laser Eye Center
Scottsdale, Arizona
Justin Schweitzer, OD, FAAO
Vance Thompson Vision
Sioux Falls, South Dakota
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Marc R. Bloomenstein, OD, FAAO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, OcuSoft, Reichert, and Sun. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, and Sun Pharma. Research/Grant Support: Allergan. Stock/Shareholder: Tearlab.
Justin Schweitzer, OD, FAAO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Aerie, Alcon, Allergan, Bausch + Lomb, EyePoint, Glaukos, Horizon, Johnson & Johnson Vision, Ocular Therapeutix, Quidel, Reichert, Sight Sciences, and Sun Pharma. Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, and Johnson & Johnson Vision.Stock/Shareholder:Equinox.
EDITORIAL DISCLOSURES
Erin K. Fletcher, MIT, director of compliance and education; Evolve; and Kate Fehlhaber, PhD, writer, have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Carl Zeiss Meditec, Glaukos, or Johnson & Johnson Vision.
